Figure 1

CHARISMA study design. Four week stabilization on a fixed dose of methotrexate was followed by randomization into seven parallel arms [13]. Intravenous infusions were administered at weeks 0, 4, 8 and 12, and observations were recorded every other week through to 20 weeks. MTX, methotrexate; MRA, tocilizumab. Reproduced, with permission, from [13]. Copyright ^© 2006 American College of Rheumatology.